Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,061 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors.
Clemente T, Galli L, Lolatto R, Gagliardini R, Lagi F, Ferrara M, Cattelan AM, Focà E, Di Biagio A, Cervo A, Calza L, Maggiolo F, Marchetti G, Cenderello G, Rusconi S, Zazzi M, Santoro MM, Spagnuolo V, Castagna A; PRESTIGIO Study Group. Clemente T, et al. Among authors: ferrara m. BMJ Open. 2024 Feb 10;14(2):e080606. doi: 10.1136/bmjopen-2023-080606. BMJ Open. 2024. PMID: 38341206 Free PMC article.
Simplification to High Genetic Barrier 2-Drug Regimens in People Living With HIV Harboring 4-Class Resistance Enrolled in the PRESTIGIO Registry.
Canetti D, Galli L, Gianotti N, Celotti A, Calza L, Gagliardini R, Rusconi S, Modica S, Cenderello G, Ferrara M, Santoro MM, Zazzi M, Castagna A; PRESTIGIO Study Group. Canetti D, et al. Among authors: ferrara m. J Acquir Immune Defic Syndr. 2020 Aug 1;84(4):e24-e28. doi: 10.1097/QAI.0000000000002378. J Acquir Immune Defic Syndr. 2020. PMID: 32598119 Free article. No abstract available.
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry.
Galli L, Parisi MR, Poli A, Menozzi M, Fiscon M, Garlassi E, Francisci D, Di Biagio A, Sterrantino G, Fornabaio C, Degli Antoni A, Angarano G, Fusco FM, D'Arminio Monforte A, Corbelli GM, Santoro MM, Zazzi M, Castagna A; PRESTIGIO Study Group. Galli L, et al. Open Forum Infect Dis. 2020 Sep 26;7(11):ofaa456. doi: 10.1093/ofid/ofaa456. eCollection 2020 Nov. Open Forum Infect Dis. 2020. PMID: 33241063 Free PMC article.
Durability of Integrase STrand Inhibitor (InSTI)-based regimen in geriatric people living with HIV in the GEPPO cohort.
Focà E, Calcagno A, Calza S, Renzetti S, Chiesa A, Siano M, De Socio G, Piconi S, Orofino G, Madeddu G, Cattelan AM, Nozza S, Ferrara M, Milic J, Celesia BM, Castelli F, Guaraldi G. Focà E, et al. Among authors: ferrara m. PLoS One. 2021 Oct 13;16(10):e0258533. doi: 10.1371/journal.pone.0258533. eCollection 2021. PLoS One. 2021. PMID: 34644336 Free PMC article.
Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection-Results of Italian Network of ACuTe HIV InfectiON (INACTION) Retrospective Study.
Muscatello A, Nozza S, Fabbiani M, De Benedetto I, Ripa M, Dell'acqua R, Antinori A, Pinnetti C, Calcagno A, Ferrara M, Focà E, Quiros-Roldan E, Ripamonti D, Campus M, Maurizio Celesia B, Torti C, Cosco L, Di Biagio A, Rusconi S, Marchetti G, Mussini C, Gulminetti R, Cingolani A, D'ettorre G, Madeddu G, Franco A, Orofino G, Squillace N, Gori A, Tambussi G, Bandera A; Inaction Study Group.. Muscatello A, et al. Among authors: ferrara m. Pathog Immun. 2020 Feb 24;5(1):8-33. doi: 10.20411/pai.v5i1.341. eCollection 2020. Pathog Immun. 2020. PMID: 32258852 Free PMC article.
Non-B subtypes account for a large proportion of clustered primary HIV-1 infections in Italy.
Bozzi G, Fabeni L, Abbate I, Berno G, Muscatello A, Taramasso L, Fabbiani M, Nozza S, Tambussi G, Rusconi S, Giacomelli A, Focà E, Pinnetti C, d'Ettorre G, Mussini C, Borghi V, Celesia BM, Madeddu G, Di Biagio A, Ripamonti D, Squillace N, Antinori A, Gori A, Capobianchi MR, Bandera A; INACTION study group. Bozzi G, et al. Sex Transm Infect. 2023 Feb;99(1):53-56. doi: 10.1136/sextrans-2021-055289. Epub 2022 Apr 20. Sex Transm Infect. 2023. PMID: 35443987 Free article.
Inflammation and intracellular exposure of dolutegravir, darunavir, tenofovir and emtricitabine in people living with HIV.
Ferrara M, Cusato J, Salvador E, Trentalange A, Alcantarini C, Trunfio M, Cannizzo ES, Bono V, Nozza S, De Nicolò A, Ianniello A, De Vivo E, D'Avolio A, Di Perri G, Bonora S, Marchetti G, Calcagno A. Ferrara M, et al. Br J Clin Pharmacol. 2023 Mar;89(3):1020-1026. doi: 10.1111/bcp.15538. Epub 2022 Oct 11. Br J Clin Pharmacol. 2023. PMID: 36115063 Free article.
96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day vs triple therapy in patients with suppressed viraemia: virological success and non-HIV related morbidity evaluation.
Di Cristo V, Adorni F, Maserati R, Annovazzi Lodi M, Bruno G, Maggi P, Volpe A, Vitiello P, Abeli C, Bonora S, Ferrara M, Cossu MV, Oreni ML, Colella E, Rusconi S. Di Cristo V, et al. Among authors: ferrara m. HIV Res Clin Pract. 2020 Feb;21(1):34-43. doi: 10.1080/25787489.2020.1734752. Epub 2020 Mar 4. HIV Res Clin Pract. 2020. PMID: 32129161 Clinical Trial.
1,061 results